Arnold Lippa

Arnold Lippa

Company: RespireRx Pharmaceuticals Inc

Job title: CEO and CSO

Seminars:

Re-Purposing Dronabinol Using Proprietary Formulations for New Therapeutic Indications, Specifically Obstructive Sleep Apnea (OSA) 9:30 am

Looking at Dronabinol’s potential to stabilize respiratory patterns and augment upper airway muscles Introducing drug formulation innovation in the form of proprietary lipid nanoparticle technology to enhance solubility and absorption Enhancing Dronabinol stability and ease of manufacturing to support commercial scaleRead more

day: Conference Day 1

Re-Purposing Dronabinol Using Proprietary Formulations for New Therapeutic Indications, Specifically Obstructive Sleep Apnea (OSA) 9:30 am

Looking at Dronabinol’s potential to stabilize respiratory patterns and augment upper airway muscles Introducing drug formulation innovation in the form of proprietary lipid nanoparticle technology to enhance solubility and absorption Enhancing Dronabinol stability and ease of manufacturing to support commercial scaleRead more

day: Day One AM

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.